Th1/Th2-regulated arginase availability modulates Leishmania infection.
Taylor-Robinson
A
A
D000818:Animals; D001119:Arginase / Q000378:metabolism*; D001120:Arginine / Q000031:analogs & derivatives* / Q000378:metabolism; D006801:Humans; D015847:Interleukin-4 / Q000378:metabolism; D018320:Leishmania major / Q000276:immunology*; D007896:Leishmaniasis / Q000201:enzymology* / Q000276:immunology; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D018417:Th1 Cells / Q000201:enzymology*; D018418:Th2 Cells / Q000201:enzymology*
D015847:Interleukin-4; C068309:N(omega)-hydroxyarginine; D001120:Arginine; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D001119:Arginase